share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/06/05 04:18

Moomoo AI 已提取核心訊息

HeartSciences received formal notice from Nasdaq on June 3, 2024, confirming its regained compliance with the $1.00 per share minimum bid price requirement. The company successfully maintained a closing bid price above $1.00 for 10 consecutive trading days through May 31, 2024, resolving the compliance issue that began on August 2, 2023.As a result of regaining compliance, HeartSciences' scheduled appeal hearing before the Nasdaq Hearing Panel on June 27, 2024, has been cancelled. The company's common stock and public warrants will continue to be listed on the Nasdaq Capital Market, maintaining its position as an AI-powered medical technology company focused on transforming ECGs for earlier heart disease detection.
HeartSciences received formal notice from Nasdaq on June 3, 2024, confirming its regained compliance with the $1.00 per share minimum bid price requirement. The company successfully maintained a closing bid price above $1.00 for 10 consecutive trading days through May 31, 2024, resolving the compliance issue that began on August 2, 2023.As a result of regaining compliance, HeartSciences' scheduled appeal hearing before the Nasdaq Hearing Panel on June 27, 2024, has been cancelled. The company's common stock and public warrants will continue to be listed on the Nasdaq Capital Market, maintaining its position as an AI-powered medical technology company focused on transforming ECGs for earlier heart disease detection.
Heart Test Laboratories, Inc.,也被稱為HeartSciences,已成功恢復納斯達克最低買盤價格要求的合規性,這得益於2024年6月3日收到的納斯達克股市LLC的信函。該公司普通股先前未能連續30個業務日達到1.00美元的最低收盤買盤價格,導致在2023年8月2日收到了納斯達克的不合規通知。為約束這一情況,HeartSciences需要在連續10個交易日中維持至少1.00美元的收盤買盤價格,這個條件在2024年5月31日之前就得到了實現。因此,原定於2024年6月27日的上訴聽證會被取消,該公司的普通股和認股權證將繼續在納斯達克上市。HeartSciences是一家醫療科技公司,利用人工智能增強心電圖以早期檢測心臟疾病,該公司在2024年6月4日的新聞發布中宣佈了合規性成就。該公司正在開發AI-ECG解決方案,並致力於為其MyoVista® wavECG™設備獲得FDA的清除。
Heart Test Laboratories, Inc.,也被稱為HeartSciences,已成功恢復納斯達克最低買盤價格要求的合規性,這得益於2024年6月3日收到的納斯達克股市LLC的信函。該公司普通股先前未能連續30個業務日達到1.00美元的最低收盤買盤價格,導致在2023年8月2日收到了納斯達克的不合規通知。為約束這一情況,HeartSciences需要在連續10個交易日中維持至少1.00美元的收盤買盤價格,這個條件在2024年5月31日之前就得到了實現。因此,原定於2024年6月27日的上訴聽證會被取消,該公司的普通股和認股權證將繼續在納斯達克上市。HeartSciences是一家醫療科技公司,利用人工智能增強心電圖以早期檢測心臟疾病,該公司在2024年6月4日的新聞發布中宣佈了合規性成就。該公司正在開發AI-ECG解決方案,並致力於為其MyoVista® wavECG™設備獲得FDA的清除。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息